Health Canada has green lit a drug previously approved for schizophrenia and depression to treat symptoms of agitation in Alzheimer’s patients – a common symptom of the disease.

Rexulti (brexpiprazole) oral tablets manufactured by Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. were issued a Notice of Compliance by the regulator, according to a company release Wednesday.

This approval was given after three 12-week randomized, double-blind, placebo-controlled studies, the release said. Global's Katherine Ward explains.

For more info, please go to [ Ссылка ]

Subscribe to Global News Channel HERE: [ Ссылка ]
Like Global News on Facebook HERE: [ Ссылка ]
Follow Global News on Twitter HERE: [ Ссылка ]
Follow Global News on Instagram HERE: [ Ссылка ]
#Health #Alzheimers #Dementia

свернуть